Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered.
van der Lugt
Jasper
J
The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand. jasper.v@hivnat.org
Gorowara
Meena
M
Avihingsanon
Anchalee
A
Burger
David
D
Ananworanich
Jintanat
J
Sringam
Kancharat
K
Kerr
Stephen
S
Wit
Ferdinand
F
Lange
Joep
J
Ruxrungtham
Kiat
K
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D019258:Saquinavir / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics
D019380:Anti-HIV Agents; D019258:Saquinavir; D019438:Ritonavir